Abetimus sodium: A new therapy for delaying the time to, and reducing the incidence of, renal flare and/or major systemic lupus erythematosus flares in patients with systemic lupus erythematosus who have a history of renal disease

Expert Opinion on Investigational Drugs

Volumn 14, Issue 1, 2005, Pages 77-88

  Cardiel, Mario H ^a  

^a HOSPITAL GENERAL DR MIGUEL SILVA   (Mexico)

Author keywords

Abetimus sodium; Anti dsDNA antibodies; LJP 394; Lupus flares; Lupus nephritis; Renal flare; Systemic lupus erythematosus

Indexed keywords

ABETIMUS; ANTIMALARIAL AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DNA ANTIBODY; DOUBLE STRANDED DNA; EPITOPE; LEFLUNOMIDE; METHOTREXATE; MOXIFLOXACIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE;

ALOPECIA; ANAMNESIS; ANTIBODY AFFINITY; ANTIBODY TITER; AREA UNDER THE CURVE; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DATA ANALYSIS; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; HUMAN; IMMUNOASSAY; INCIDENCE; INFERTILITY; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; OPTIMAL DRUG DOSE; OVARY INSUFFICIENCY; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS;

CLINICAL TRIALS; HUMANS; INCIDENCE; KIDNEY DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; OLIGONUCLEOTIDES; TIME FACTORS;

EID: 12744275048     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.1.77     Document Type: Article

References (20)

1. GLADMAN DD, UROWITZ MB: Prognosis, mortality and morbidity in systemic lupus erythematosus. In: Dubois' lupus erythematosus (6th Edition). DJ Wallace, BH Hahn (Eds), Lippincott Williams & Wilkins, Baltimore, MD, USA (2002):1255-1274.
2. TAN EM, COHEN AS, FRIES JF et al.: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. (1982) 25:1271-1277.
3. HAHN BH: Antibodies to DNA. N. Engl. J. Med. (1998) 338:1359-1368.
4. SCHUR PH, SANDSON J: Immunologic factors and clinical activity in systemic lupus erythematosus. N. Engl. J. Med. (1968) 278:533-538.
5. TOJO T, FRIOU GJ: Lupus nephritis: varying complement-fixing properties of immunoglobulin G antibodies to antigens of cell nuclei. Science (1968) 161:904-906.
6. LEFKOVITH JB, KIEHL M, RUBENSTEIN J et al.: Heterogeneity and clinical significance of glomerular-binding antibodies in systemic lupus erythematosus. J. Clin. Invest. (1996) 98 1373-1380.
7. BRINKMAN K, TERMAAT R, BERDEN JH, SMEENK RJ: Anti-DNA antibodies and lupus nephritis: the complexity of crossreactivity. Immunol. Today (1990) 11:232-234.
8. WINFIELD JB, FAIFERMAN I, KOFFLER D: Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus: association with high avidity anti-native DNA antibody with glomerulonephritis. J. Clin. Invest. (1977) 59 90-96.
9. QUISMORIO FP Jr: Clinical application of serologic abnormalities in systemic lupus erythematosus. In: Dubois' lupus erythematosus (5th Edition). DJ Wallace, BH Hahn (Eds), Lippincott Williams & Wilkins, Baltimore, MD, USA (1997):925-942.
10. SMEENK RJT, VAN DEN BRINK HG, BRINKMAN K, TERMAAT RM, BERDEN JHM, SWAAK AJG: Anti-dsDNA: choice of assay in relation to clinical value. Rheumatol. Int. (1991) 11:101-107.
11. TER BORG EJ, HORST G, HUMMEL EJ, LIMBURG PC, KALLENBERG CG: Measurement of increases in anti-double-stranded DNA antibody levels as a major predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum. (1990) 33 634-643.
12. CERVERA R, KHAMASHTA MA, FONT J et al.: Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. Medicine (1999) 78:167-175.
13. KOFFLER D, SCHUR PH, KUNKEL HG: Immunological studies concerning the nephritis of systemic lupus erythematosus. J. Exper Med. (1967) 126:607-623.
14. SWAAK AJ, GROENWALD J, BRONSVELD W: Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann. Rheum. Dis. (1986) 45:359-366.
15. HO A, MAGDER LS, BARR SG, PETRI M: Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum. (2001) 44:2342-2349.
16. BIJL M, HORST G, BOOTSMA H, LIMBURG PC, KALLENBERG CG: Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk. Ann. Rheum. Dis. (2003) 62 6):534-539.
17. WEINSTEIN A, BORDWELL B, STONE B, TIBBETTS C, ROTHFIELD NF: Antibodies to native DNA and serum complement (C3) levels: application to diagnosis and classification of systemic lupus erythematosus. Am. J. Med. (1983) 74:206-216.
18. BOOTSMA H, SPRONK P, DERKSEN R et al.: Prevention of relapses is systemic lupus erythematosus. Lancet (1995) 354 1595-1599.
19. ALARCON-SEGOVIA D, TUMLIN JA, FURIE RA et al.: LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus. Arthritis Rheum. (2003) 48(2):442-454.
20. STRAND V, ARANOW C, CARDIEL MH et al.: Improvement in health-related quality of life in SLE patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo. Lupus (2003) 12:677-686.